OBJECTIVE： To evaluate the effectiveness of mifepristone in the treatment of abnormal uterine bleeding in Chinese women during perimenopause period， and to provide evidence-based reference in clinic. METHODS： Retrieved from CJFD， SinoMed， VIP， Wanfang database， randomized controlled trials （RCTs） about mifepristone in the treatment of abnormal uterine bleeding in Chinese women during perimenopause period were collected， data extraction was conducted for clinical studies meeting inclusion criteria. Meta-analysis was conducted by using Stata 8.0 statistical software after quality evaluation with Cochrane manual 5.1.0. RESULTS： A total of 49 RCTs were included， involving 5 082 patients. Meta-analysis showed that the response rate of mifepristone high-dose group （12.5 mg/d）was significantly higher than that of mifepristone low-dose group （≤6.5 mg/d）[OR＝2.13，95％CI（1.53，2.97），P＜0.001]， and response rate of mifepristone group was significantly higher than that of progesterone drug group [OR＝6.05，95％CI（3.92，9.34），P＜0.001]. There was no statistical significance in response rate between mifepristone group and estrogen drug group [OR＝1.52，95％CI（0.45，5.16），P＝0.499]. CONCLUSIONS： Mifepristone is better than progesterone drug and similar to hormone drug in the treatment of abnormal uterine bleeding during perimenopause period. High-dose of mifepristone is better than low-dose of mifepristone in the treatment of abnormal uterine bleeding during perimenopause period.